

ORIGINAL ARTICLE

A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome

P López-Jornet, F Camacho-Alonso, P Andujar-Mateos

Department of Oral Medicine, University of Murcia, Murcia, Spain

OBJECTIVE: To apply a tongue protector with habit-modifying therapy through self-control, in the patients with burning mouth syndrome (BMS).

METHODS: A prospective, randomized study was made of 65 consecutive patients with BMS. Fifty subjects were randomized to two groups: group A (informed) and group B (informed and the application of a tongue protector). The symptoms were evaluated by VAS, whereas the psychological profile was assessed using the HAD, with application of the quality of life questionnaires SF-36 and OHIP-49. The duration of treatment was 2 months.

RESULTS: Fifty patients (46 females and 4 males) completed the study. The VAS scores in group B were 8.2 at baseline and 4.5 after 2 months. The respective scores in group A were 7.1 and 5.6 – the differences between the two groups being significant ($P < 0.001$). In group B the OHIP-49 yielded lower scores for most of the scales, with significant differences vs group A. In group B the SF 36 yielded significant differences vs group A in physical role, bodily pain, general health and emotional role.

CONCLUSIONS: Parafunctional traumatism of the tongue should be taken into account in the pathogenesis of BMS with a view to exploring new therapeutic options.

Oral Diseases (2011) 17, 277–282

Keywords: burning mouth syndrome; primary; secondary; parafunctional habits; tongue; treatment

Introduction

Burning mouth syndrome (BMS) is characterized by a subjective sensation of burning or itching of the oral mucosa, in the absence of clinical and laboratory test data capable of accounting for the symptoms, and with a duration of at least 4–6 months (Grushka *et al*, 2006; Fedele *et al*, 2007; Klasser *et al*, 2008). The prevalence

of BMS varies between 0.7% and 4.5% (Scala *et al*, 2003; Maltzman-Tseikhin *et al*, 2007). It is mainly seen in postmenopausal women (Baker *et al*, 2005). There is debate in the medical literature regarding the etiopathogenesis of the disorder, and several factors and concepts have been proposed (Rojo *et al*, 1994; Bergdahl *et al*, 1995; Lamey, 1998; Danhauer *et al*, 2002; Scala *et al*, 2003; Zakrzewska *et al*, 2003; Sardella *et al*, 2006; Patton *et al*, 2007; López-Jornet *et al*, 2008). The postulated causal factors have been grouped into local factors (infections, irritants, etc.), systemic factors (diabetes mellitus, anemia through iron or folic acid deficiency, etc.), and psychogenic factors; but these causal factors contradict the definition of BMS and so constitute another disease condition separate from BMS. BMS is considered to be idiopathic/primary when the cause is impossible to determine (Klasser *et al*, 2008) and secondary when it is possible to identify etiologic factors for the syndrome. Some investigators have suggested that the disorder may be a manifestation of somatization, whereas others have reported it to be more closely related to neuropathic pain than to somatoform chronic pain syndromes.

Parafunctional habits such as tongue thrusting or certain tics in the form of continuous rubbing of the teeth or dentures, lip, cheek, or tongue nibbling, compulsive movements and hyperactivity of the tongue may contribute to induce and maintain the syndrome (López-Jornet *et al*, 2009a). Pain in BMS is most often bilateral and symmetrical in the anterior two-thirds of the tongue (71–78%), followed by the dorsal and lateral surfaces of the tongue, the anterior portion of the hard palate, and the lip mucosa and gingiva. The condition often manifests in several locations (Scala *et al*, 2003).

Considering the chronic nature of BMS and its prevalence, optimum treatment must be established, since no effective therapies have been developed to date. Many treatments have been tested with a view to securing symptoms relief (Maina *et al*, 2002), including benzodiazepines, tricyclic antidepressants, gabapentin, serotonin reuptake inhibitors, lipoic acid, and cognitive behavioral therapy – with variable results. It is therefore important to study and understand the

Correspondence: Pía López-Jornet, Clínica Odontológica Universitaria, Medicina Bucal, Hospital Morales Meseguer, Avda. Marqués de los Vélez s/n, 30008 Murcia, Spain. Tel: +34 968 398588, Fax: +34 968 398576, E-mail: majornet@um.es

Received 13 May 2010; revised 16 June 2010; accepted 27 June 2010

physiopathological mechanisms of stomatodynia to select the best possible treatment (Femiano *et al*, 2004; Gremeau Richard *et al*, 2004; Maina *et al*, 2005; Minguéz Serra *et al*, 2007; Klasser *et al*, 2008; Carbone *et al*, 2009; Lopez-Jornet *et al*, 2009b).

The proposed pharmacological protocols have not consistently proved to be predictable and effective in all BMS subjects, in this sense the aim of the this study was to apply a tongue protector with habit-modifying therapy through self-control, and to evaluate the symptoms and quality of life in the patients with BMS.

Methods

A prospective, randomized study was made of 65 consecutive patients with BMS seen in the Department of Oral Medicine (University of Murcia, Spain). The study was carried out during the period between March 2007 and June 2009, and was authorized by the Bioethics Committee of the University of Murcia. A sample size was not calculated before starting the trial, as we were not able to predict the effect of the investigated treatment.

Inclusion criteria for participating in the study were a clinical history of continuous symptoms of oral burning or pain on a daily or almost daily basis, during all or part of the day for more than 6 months, without paroxysms, and independent of the nervous pathway. Likewise, the included patients presented no clinical abnormalities that could account for the symptoms. Furthermore, the patients had to present normal blood test findings (complete blood count, blood glucose, serum iron and transferrin levels, serum vitamin B12,

and folate), and were required to provide informed consent (Gremeau Richard *et al*, 2004). Patients with pain attributable to other conditions (angiotensin-converting enzyme inhibitor use, candidiasis, lichenoid reactions, sores, tongue atrophy, etc.) were excluded, as were those presenting problems with dentures, biochemical anomalies and a history of hypersensitivity or allergy to the material used. Patients with known neurological disorders and those previously treated, even irregularly, with antidepressants, anticonvulsants, other psychotropic drugs, or psychological therapy were also excluded from the study. Patients occasionally using anxiolytics to induce sleep were accepted. Subjects with signs of lingual and labial parafunctional activity were also considered (tongue rubbing, lip or cheek nibbling) (Figure 1).

Primary outcome variable: oral symptoms were registered using a visual analog scale (VAS) consisting of a 10-cm vertical line marked from 0 (= no pain) to 10 (= most severe pain experienced) (Maina *et al*, 2005). Patients were asked to indicate the mean pain intensity for the 2 weeks preceding the consultation. The difference between baseline and the endpoint scores numerically expressed symptoms variation.

The Hospital Anxiety and Depression scale (HAD) was used to evaluate the patient psychological profile. The HAD comprises two subscales relating to anxiety and depression. Each subscale contains seven items pertaining to mood disorder. On analyzing the HAD scales, scores of over 10 indicated the probable presence of anxiety or depression, scores of seven or less indicated no significant anxiety or depression, and scores of 8–10 were taken to be of borderline significance (Bjelland *et al*, 2002).




Figure 1 Flow diagram

The Oral Health Impact Profile (OHIP-49) is an instrument used to measure oral health. With the OHIP-49, each item was scored as follows: 0 = 'never', 1 = 'hardly ever', 2 = 'occasionally', 3 = 'fairly often', and 4 = 'very often'. The OHIP-49 is divided into seven different domains, and the possible score range for each domain is: 'functional limitation' (nine items), from 0 to 36; 'physical pain' (nine items), from 0 to 36; 'psychological discomfort' (five items), from 0 to 20; 'physical disability' (nine items), from 0 to 36; 'psychological disability' (six items), from 0 to 24; 'social disability' (five items), from 0 to 20; 'handicap' (six items), from 0 to 24; and finally 'overall OHIP score' (49 items), from 0 to 196. In this instrument, higher scores indicate a poorer state of health (Lopez and Baelum, 2006).

The Short Form 36 (SF-36) Health Survey Questionnaire in turn has been designed to evaluate quality of life. The standard version of the SF-36 contains eight areas (Alonso *et al*, 1995): 'physical functioning', 'physical role limitations', 'bodily pain', 'general medical health', 'vitality', 'social functioning', 'emotional role limitations', and 'mental health'. The scoring system is designed in such a way that higher scores indicate better health; thus, 0 is the worst state of health and 100 the ideal state of health.

Every new patient seen at the Oral Medicine Unit who met the eligibility criteria was asked to enter the trial. After being informed about the scope and methods of the study, the subjects who accepted signed the written informed consent form, and then were randomly allocated to one of the two arms of the study. The random allocation sequence was generated using software available online at <http://graphpad.com/quickcalcs/randomize1>. All the patients were instructed not to use any product for BMS during inclusion in the study.

All the patients in group A were informed in detail about their illness, and were instructed not to rub their tongue against their teeth and/or dentures. A self-control technique was used to this effect, the patients being given 10 printed habit-modifying reminder points to be placed in visible places. The same measures were adopted in group B, although in this case the patients were moreover programmed for tongue protector placement. The protector consisted of a transparent, low-density polyethylene sheath covering the tongue from the tip to the posterior third. These tongue protector s were single-use devices measuring 0.1 mm in thickness, with a standard size (67 mm in length and 66 mm wide), and were custom manufactured by our group (Figure 2). Each patient received a kit with the protectors and the reminder points for treatment. Instructions were provided on their use – the protector being worn during the daytime for a period of 2 months. We recommended use of the protector 15 min/three times a day with the therapeutic aim of avoiding continuous rubbing against the teeth and/or dentures.

The patients in both groups were examined at the start of treatment and again after 2 months. One month after inclusion, the investigator called the patients in both groups by telephone as a reminder and to reinforce motivation. All patients completed the HAD question-



Figure 2 View of the tongue protector. Manufactured by our group with a standard size (67 mm in length and 66 mm wide)

naire and the quality of life instruments OHIP-49 and SF-36 on each of the visits (after 0 and 2 months). On these visits the subjects were also questioned about tolerability and possible adverse effects.

The data were analyzed using the spss version 12.0 statistical package (SPSS® Inc., Chicago, IL, USA). A descriptive study was made of each variable. The associations between the different qualitative variables were studied using Pearson's chi-squared test. We used the Student's *t*-test for two independent samples in application to quantitative variables – in each case determining whether the variances were homogeneous. A probability of less than $P \leq 0.05$ was accepted as significant.

Results

Sixty-five patients referred to the Department of Oral Medicine for oral burning sensation were assessed for eligibility: 12 failed to meet the inclusion criteria and three refused to participate in the study. A total of 50 subjects were therefore finally included: 46 females and four males, aged 61.18 ± 12.27 years (range 37–84). Table 1 shows the homogeneity of the two patient groups on the day of inclusion in the study. During the 2-month duration of the study there were no dropouts in either group, and no adverse effects were observed.

The VAS scores in group B (tongue protector group) were 8.2 at baseline and 4.5 after 2 months. The respective scores in group A were 7.1 and 5.6) – the differences between the two groups being significant ($P < 0.001$) (Table 2). Regarding the HAD, the scores showed no significant differences for either of the groups during the course of the study.

In group B the OHIP-49 (Table 3) yielded lower scores (i.e., better quality of life) in all domains, with significant differences between the two study time points

Table 1 Homogeneity of the study groups on day 0 (baseline) in relation to age, gender and the VAS and HAD scores (Student's *t*-test and Pearson's chi-squared)

Age, gender, VAS, HAD day 0	Group B (n = 25)	Group A (n = 25)	P-value
Age: mean \pm s.d.	60.96 \pm 11.97	61.40 \pm 12.81	0.901
Gender			
Male: n (%)	2 (8)	2 (8)	1.000
Female: n (%)	23 (92)	23 (92)	
VAS: mean \pm s.d.	8.2 \pm 2.1	7.1 \pm 2.1	0.087
HAD: mean \pm s.d.			
Depression	9.28 \pm 6.00	8.96 \pm 6.09	0.852
Anxiety	11.12 \pm 5.27	11.24 \pm 5.67	0.939

VAS, visual analog scale; HAD, hospital anxiety-depression scale; s.d., standard deviation.

(day 0 and after 2 months). Thus, the total OHIP-49 score in group B was 62.9 ± 34.0 on day 0 and 44.5 ± 28.1 after 2 months. In contrast, group A showed only minimum changes, with a total score of 55.4 ± 4 on day 0 and 53.7 ± 35.3 after 2 months. On comparing the two patient groups, significant differences were observed in the scales or domains corresponding to functional limitation, bodily pain, psychological discomfort, physical disability, psychological disability, and total score.

Lastly, as refers to the SF-36 (Table 4), the patients subjected to tongue protector treatment (group B) showed improvement in the scores between day 0 and the end of treatment (2 months) in practically all the subscales, whereas only minimal changes were observed in group A. On comparing the two groups, significant differences were recorded for physical functioning,

Table 2 Evolution of the VAS and HAD scores during the two months of the study (Student's *t*-test)

	Group B (n = 25): mean \pm s.d.	Group A (n = 25): mean \pm s.d.	
VAS and HAD	Evolution (day 0 to 2 months)	Evolution (day 0 to 2 months)	P-value
VAS	(8.2 \pm 2.1) – (4.5 \pm 2.2) = 3.6 \pm 2.2	(7.1 \pm 2.1) – (5.6 \pm 1.5) = 1.4 \pm 1.6	<0.001
HAD			
Depression	(9.28 \pm 6.00) – (8.28 \pm 5.93) = 1.00 \pm 3.73	(8.96 \pm 6.09) – (8.92 \pm 6.13) = 0.04 \pm 0.20	0.205
Anxiety	(11.12 \pm 5.27) – (11.20 \pm 6.59) = –0.08 \pm 3.39	(11.24 \pm 5.67) – (11.04 \pm 5.43) = 0.20 \pm 1.00	0.694

s.d., standard deviation; VAS, visual analog scale; HAD, hospital anxiety-depression scale.

Table 3 Evolution of the OHIP-49 score during the two months of the study (Student's *t*-test)

	Group B (n = 25): mean \pm s.d.	Group A (n = 25): mean \pm s.d.	
OHIP-49	Evolution (day 0 to 2 months)	Evolution (day 0 to 2 months)	P-value
Functional limitation	(10.80 \pm 5.98) – (7.72 \pm 5.53) = 3.84 \pm 5.24	(12.36 \pm 6.83) – (12.28 \pm 6.80) = 0.08 \pm 0.64	0.001
Bodily pain	(15.80 \pm 8.31) – (11.16 \pm 8.06) = 4.64 \pm 7.43	(14.16 \pm 7.65) – (13.56 \pm 8.37) = 0.68 \pm 2.35	0.014
Psychological discomfort	(10.40 \pm 5.82) – (6.84 \pm 5.55) = 3.56 \pm 5.07	(7.52 \pm 6.49) – (7.52 \pm 6.77) = 0.00 \pm 1.15	0.001
Physical disability	(9.08 \pm 6.95) – (6.12 \pm 6.72) = 3.12 \pm 5.36	(8.88 \pm 7.16) – (8.88 \pm 7.16) = 0.00 \pm 0.00	0.005
Psychological disability	(10.04 \pm 6.26) – (6.76 \pm 6.22) = 3.28 \pm 6.22	(5.08 \pm 5.72) – (4.64 \pm 5.93) = 0.44 \pm 1.35	0.031
Social disability	(3.00 \pm 5.38) – (2.52 \pm 4.77) = 0.72 \pm 5.99	(3.12 \pm 5.46) – (2.96 \pm 5.49) = 0.16 \pm 0.80	0.646
Handicap	(3.84 \pm 6.22) – (2.36 \pm 5.64) = 1.48 \pm 5.16	(4.32 \pm 4.66) – (3.88 \pm 4.79) = 0.46 \pm 1.56	0.358
Total OHIP-49	(62.96 \pm 34.03) – (44.52 \pm 28.17) = 18.44 \pm 29.53	(55.40 \pm 34.33) – (53.72 \pm 35.30) = 1.92 \pm 4.93	0.008

s.d., standard deviation.

Table 4 Evolution of the SF-36 score during the two months of the study (Student's *t*-test)

	Group B (n = 25): mean \pm s.d.	Group A (n = 25): mean \pm s.d.	
SF-36	Evolution (day 0 to 2 months)	Evolution (day 0 to 2 months)	P-value
Physical functioning	(57.40 \pm 34.12) – (67.60 \pm 38.04) = –10.20 \pm 25.26	(54.00 \pm 38.78) – (54.20 \pm 39.01) = –0.20 \pm 1.00	0.054
Physical role	(26.50 \pm 42.43) – (58.00 \pm 49.23) = –35.50 \pm 45.31	(44.00 \pm 50.66) – (44.00 \pm 50.66) = 0.00 \pm 0.00	<0.001
Bodily pain	(24.00 \pm 31.38) – (39.50 \pm 36.48) = –15.50 \pm 26.65	(51.22 \pm 28.61) – (54.22 \pm 29.11) = –3.00 \pm 7.63	0.029
General health	(32.99 \pm 29.38) – (44.16 \pm 29.34) = –11.16 \pm 23.31	(42.33 \pm 27.94) – (42.99 \pm 29.13) = –0.66 \pm 3.33	0.031
Vitality	(39.80 \pm 25.55) – (52.00 \pm 30.31) = –12.20 \pm 23.80	(47.80 \pm 27.99) – (50.80 \pm 30.40) = –3.00 \pm 8.03	0.073
Social functioning	(47.00 \pm 39.73) – (59.50 \pm 41.02) = –12.50 \pm 25.51	(60.00 \pm 32.87) – (62.50 \pm 34.23) = –2.50 \pm 10.20	0.075
Emotional role	(34.66 \pm 47.60) – (55.99 \pm 48.80) = –21.33 \pm 40.68	(42.66 \pm 47.64) – (43.99 \pm 46.86) = –1.33 \pm 6.66	0.019
Mental health	(36.16 \pm 27.45) – (51.52 \pm 29.08) = –15.36 \pm 27.89	(47.04 \pm 27.76) – (52.00 \pm 30.19) = –4.96 \pm 17.40	0.120

s.d., standard deviation.

physical role, bodily pain, general health and emotional role (Table 4).

Discussion

Our results indicate clinical improvement among the patients for BMS. The VAS scores were modified in both groups during the treatment period (0–2 months), although significant differences were observed between them. On only considering overall improvement, the mean reduction in VAS score observed in group B was from 8.2 at baseline to 4.5 at the end of the study. The mean 1.4-point decrease in pain intensity observed in this study in group A may appear small, but obviously all patients did not respond in the same way to the active treatment.

Burning mouth syndrome is a diagnostic and therapeutic challenge because of its etiopathogenic variability (Patton *et al*, 2007; Kasser *et al*, 2008). The latest studies suggest that psychopathological factors may play an important role in the disorder, in correlation with the multifactorial origin of BMS. A strong psychological component in BMS has been clearly identified in the last decade. It has been suggested that somatic complaints from unfavorable life experiences associated with chronic pain may influence both individual personality and mood changes. Bergdahl *et al* (1995) studied the effect of cognitive therapy on resistant BMS. Their patients were randomly divided into two equal groups: a therapy group was subjected to cognitive therapy and an attention/placebo group served as control group. The authors used a VAS to estimate the intensity of BMS, and they found it to be significantly reduced in the therapy group after cognitive therapy was completed (12–15 one-hour sessions once a week).

Gremau-Richard *et al* (2004) published a randomized double-blind, multicenter parallel group study in which topical clonazepam improved the stomatodynia symptoms (two-thirds of the included subjects). However, this treatment was not effective in all subjects. Several studies have assessed systemic therapies, including amisulpride, selective serotonin reuptake inhibitor antidepressants such as paroxetine and sertraline, trazodone and 0.25% capsaicin, with variable results (Minguez Serra *et al*, 2007; Patton *et al*, 2007). The use of lipoic acid in BMS patients was presented as a promising alternative for management of the symptoms, with high levels of improvement – although lipoic acid is not effective in many cases (Carbone *et al*, 2009; Lopez Jornet *et al*, 2009b).

Oral parafunctional habits have been widely implicated as factors that intervene in the development and perpetuation of other syndromes (Dworkin and LeResche, 1992; Axéll, 2008) such as for example temporomandibular joint disorders. Parafunctional activity is defined as the potential lesions (depending on the tolerance of the individual in question) caused by a series of movements that occur in parallel to normal function, although lacking a functional purpose, and which generate traumatic forces characterized by an abnormal direction, excessive intensity, and a frequent

and lasting character. Any type of hyperactivity – in this case of the tongue and/or lips – occurring without functional objectives or in a way that proves inadequate for the stomatognathic system, is regarded as parafunctional activity. In this context, the tongue protector used in our study offered protection, as it avoided direct friction or rubbing of the tongue mucosa against the teeth and/or dentures protect the tongue regarding the changes in temperature and taste, salivary flow (increased) although its use could also exert a placebo effect.

The management of BMS symptoms is the greatest challenge related with this syndrome. Several systemic and local therapies have been suggested to treat these patients, with frequently unsatisfactory results. Maybe this fact explains the high receptivity of BMS patients for new therapies and the good adherence to treatment observed in our study.

A possible confounding factor is represented by occult candidiasis. Some authors reported evidence for candida-induced burning mouth even in the absence of objective signs (Terai and Shimahara, 2007), thus suggesting the advisability of routine treatment with antifungal agents for at least 1 week before confirming the diagnosis of BMS. As this issue was not taken into account in the present protocol, some patients may have had occult candidiasis, and therefore perhaps failed to respond to treatment.

Moreover, as the evaluation of symptoms could be altered by the interpersonal relationship between the patient and investigator, the same examiner followed up on all of the patients in the study, to ensure that the results would be comparable.

It is important to consider quality of life in BMS patients, as the impact of the disease on the different domains or subscales is considerable. Accordingly, in our study use was made of two validated instruments, the OHIP-49 and SF-36. Our results show significant improvements in the OHIP-49 score in the group of patients treated with the tongue protector, in the domains relating to functional limitation, bodily pain, psychological discomfort, physical disability, psychological disability, and in the total score.

As regards the SF-36, after 2 months of treatment group B showed improvement in all the domains, with significant differences *vs* group A as regards the subscales used to assess physical functioning, physical role, bodily pain, general health, and emotional role. Thus, the tongue protector could be an alternative for the management of patients with BMS. Self-inflicted damage secondary to parafunctional activity of the tongue should be taken into consideration in the pathogenesis of BMS, with a view to developing new management strategies.

Although our working hypothesis may be supported statistically, we included only a small patient series treated for a period of 2 months – a fact that makes it difficult to draw firm conclusions. Future studies are needed to reproduce our findings in larger series, over longer periods of time and involving an adequate sample of patients.

It is essential to deepen our understanding of the physiopathological mechanisms of burning mouth to select the best treatment and develop new therapies which may use different mechanisms. Future research moreover should focus on the long-term effects of treatment and on the quality of life of patients with burning mouth syndrome, to establish the clinical impact of such interventions.

References

- Alonso J, Prieto L, Anto JM (1995). La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. *Med Clin* **104**: 771–776.
- Axéll T (2008). Treatment of smarting symptoms in the oral mucosa by appliance of lingual acrylic splints. *Swed Dent J* **32**: 165–169.
- Bergdahl J, Anneroth G, Perris H (1995). Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study. *J Oral Pathol Med* **24**: 213–215.
- Bjelland I, Dhal A, Huag T, Neckelmann D (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *J Psychosom Res* **2**: 69–77.
- Carbone M, Pentenero M, Carozzo M, Ippolito A, Gandolfo S (2009). Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: a double-blind, randomized, placebo-controlled study. *Eur J Pain* **13**: 492–496.
- Danhauer SC, Miller CS, Rhodus NL, Carlson CR (2002). Impact of criteria-based diagnosis of burning mouth syndrome on treatment outcome. *J Orofac Pain* **16**: 305–311.
- Dworkin SF, LeResche L (1992). Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specification, critique. *J Craniomandib Disord Facial Oral Pain* **6**: 301–355.
- Fedele S, Frichione G, Porter SR, Mignogna MD (2007). Burning mouth syndrome (stomatodynia). *QJM* **100**: 527–530.
- Femiano F, Gombos F, Scully C (2004). Síndrome de boca ardiente. Estudio de la psicoterapia, medicación con ácido alfa-lipoico y combinación de terapias. *Med Oral* **9**: 8–13.
- Greteau Richard C, Woda A, Navez ML et al (2004). Topical clonazepam in stomatodynia: a randomized placebo-controlled study. *Pain* **188**: 51–57.
- Grushka M, Ching V, Epstein J (2006). Burning mouth syndrome. *Adv Otorhinolaryngol* **63**: 278–287.
- Klasser GD, Fischer DJ, Epstein JB (2008). Burning mouth syndrome: recognition, understanding, and management. *Oral Maxillofac Surg Clin North Am* **20**: 255–257.
- Lamey PJ (1998). Burning mouth syndrome: approach to successful management. *Dent Update* **25**: 298–300.
- Lopez R, Baelum V (2006). Spanish version of the Oral Health Impact Profile (OHIP-Sp). *BMC Oral Health* **6**: 1–8.
- Lopez-Jornet P, Camacho-Alonso F, Leon-Espinosa S (2009b). Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. *J Oral Rehabil* **36**: 52–57.
- López-Jornet P, Camacho Alonso F, Lucero Berdugo M (2008). Quality of life in patients with burning mouth syndrome. *J Oral Pathol Med* **37**: 389–394.
- López-Jornet P, Camacho-Alonso F, Leon-Espinosa S (2009a). Burning mouth syndrome, oral parafunctions, and psychological profile in a longitudinal case study. *J Eur Acad Dermatol Venereol* **23**: 363–365.
- Maina G, Vitalucci A, Gandolfo S, Bogetto F (2002). Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. *J Clin Psychiatry* **63**: 38–43.
- Maina G, Albert U, Gandolfo S, Vitalucci A, Bogetto F (2005). Personality disorders in patients with burning mouth syndrome. *J Personal Disord* **19**: 84–89.
- Maltsman-Tseikhin A, Moricca P, Niv D (2007). Burning mouth syndrome: will better understanding yield better management? *Pain Pract* **7**: 151–162.
- Minguez Serra MP, Salort Llorca C, Silvestre Donat FJ (2007). Pharmacological treatment of burning mouth syndrome: a review and update. *Med Oral Pathol Oral Cir Bucal* **12**: E299–E304.
- Patton LL, Siegel MA, Benoliel R, De Laat A (2007). Management of burning mouth syndrome: systematic review and management recommendations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* **103**(Suppl. S39): e1–e13.
- Rojo L, Silvestre FJ, Bagan JV, de Vicente T (1994). Prevalence of psychopathology in burning mouth syndrome. *Oral Surg Oral Med Oral Pathol* **78**: 312–316.
- Sardella A, Lodi G, Demarosi F, Uglietti D, Carrassi A (2006). Causative or precipitating aspects of burning mouth syndrome: a case-control study. *J Oral Pathol Med* **35**: 466–471.
- Scala A, Checchi L, Montevocchi M, Marini I, Giamberardino MA (2003). Update on burning mouth syndrome: overview and patient management. *Crit Rev Oral Biol Med* **14**: 275–291.
- Terai H, Shimahara M (2007). Tongue pain: burning mouth syndrome vs Candida associated lesion. *Oral Dis* **13**: 440–442.
- Zakrzewska JM, Forssell H, Glenney A (2003). Interventions for the treatment of burning mouth syndrome: a systematic review. *J Orofacial Pain* **17**: 293–300.

Copyright of Oral Diseases is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.